title: Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
abstract: BACKGROUND
  It is vital that after, renal transplantation, immunosuppression is efficacious and causes few complications. It is especially important that hyperlipidaemia, hypertension and toxic influences should be avoided because these conditions can reduce patient and transplant survival. Many studies have demonstrated beneficial effects of tacrolimus in comparison with cyclosporine with regard to these conditions. These results have suggested that a conversion to tacrolimus from cyclosporine is advantageous. Our study investigated whether patients with deteriorating renal functions can profit from this conversion.
  
  
  METHODS
  Thirty patients with a renal transplant were studied retrospectively, using data recorded from 3 years before to 3 years after conversion from cyclosporine to tacrolimus.
  
  
  RESULTS
  While renal function (glomerular filtration rate [GFR]) deteriorated progressively under cyclosporine, it stabilised and even improved under tacrolimus (creatinine: Delta(Cyc)=+1.4 mg/d; Delta(Tac=)-0.7 mg/dl; GFR: Delta(Cyc)=-35 ml/min; Delta(Tac)=14 ml/min). In addition, uric acid level (7.0 vs. 6.4 mg/dl, p<0.05) and cholesterol level (258 vs. 225 mg/dl, p<0.05) were both significantly lower under tacrolimus.
  
  
  CONCLUSIONS
  Conversion from cyclosporine to tacrolimus is recommended for patients with a kidney transplant, in which there has been a progressive fall in renal function. It leads to stabilisation or even improvement of transplant function and a reduction in cardiovascular risk factors.
authors.affiliation: Nephrologisches Zentrum Emsland, Gymnasialstr. 6, 49808 Lingen, Germany.
authors.forename: Helge
authors.initials: H
authors.lastname: Hohage
authors.forename: U
authors.initials: U
authors.lastname: Welling
authors.forename: M
authors.initials: M
authors.lastname: Heck
authors.forename: M
authors.initials: M
authors.lastname: Zeh
authors.forename: U
authors.initials: U
authors.lastname: Gerhardt
authors.forename: B M
authors.initials: BM
authors.lastname: Suwelack
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D016030:Kidney Transplantation; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D016559:Tacrolimus / Q000008:administration & dosage* / Q000097:blood; D014527:Uric Acid / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D014527:Uric Acid; D016572:Cyclosporine; D002784:Cholesterol; D003404:Creatinine; D009173:Mycophenolic Acid; D011241:Prednisone; D016559:Tacrolimus